EGFR expression

Interestingly, heparin did not enhance the proliferative activity of treated cells, likely because it binds to the heparin-binding domain of HB-EGF, sequestering it from interaction with membrane-associated heparan sulfate proteoglycans and preventing matricrine activation. These findings suggest that combining HB-EGF-targeting strategies could significantly reduce mitogenic activation and induce cancer cell death in tumors with high EGFR and proHB-EGF expression.

Serum SCC-Ag showed superior prognostic performance compared with individual IHC markers, and may be useful for postoperative risk stratification in VSCC. Combined biomarker panels, including p53, PD-L1, EGFR and p16, yielded promising sensitivity, supporting future strategies.

The platform has potential for broad applicability, including simultaneous delivery of diverse or synergistic payloads. These findings represent an important advance toward precision nanomedicine approaches in radionuclide therapy.

P3, N=400, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.

These findings underscore the important role of EGFR expression in predicting the efficacy of NIR-PIT in the management of head and neck cancer, and highlight the significance of incorporating EGFR assessment in patient selection and optimized treatment strategies. Further studies are needed to elucidate the role that these other potential predictors, including tumor immune response markers, play in NIR-PIT outcomes.

P2, N=52, Not yet recruiting, Fudan University

In vivo and ex vivo PAI BP was moderately to highly correlative to percent area IHC EGFR expression (r = 0.65 and 0.54, p < 0.05, respectively) and the in vivo 100 J/cm2 treatment group demonstrated significantly lower BP than the controls. PAI emerges as a promising tool for tracking early molecular changes in HNC, with potential clinical applications.

The nanoparticle was developed by transfection of four plasmids (Gag-Cas9, Gag, sgRNA, VSV-G Azi) into 293T cells to form a type of bionanoparticle and modifying it with a targeted polymer material (DBCO-PEG-FA), and it showed a cancer-targeted property, faster cancer cellular uptake, higher gene editing efficiency with lower off-target effects, and therapy efficacy in mice, indicating a translational prospect. In conclusion, the study provides a recombinant bionanoparticle in vitro expressing a Cas9 gene editing system and offers a potential strategy for gene therapy of EGFR mutant lung cancer.

P1/2, N=144, Recruiting, Engeneic Pty Limited | Not yet recruiting --> Recruiting

Molecular docking results showed that ertugliflozin had the strongest intermolecular binding to EGFR and that ertugliflozin improved the viability of high-glucose (HG)/high-lipid combined hypoxia-reoxygenation-injured (HG/HP + H/R) cardiomyocytes and inhibited EGFR expression in cardiomyocytes...Molecular docking and cell experiments further confirmed that SGLT2i-ERTU improves HG/HP + H/R myocardial cell injury by targeting EGFR. Our study deepened the pharmacological mechanism of SGLT2is in the treatment of T2DM combined with CHD and provided a new perspective and therapeutic basis for future experimental research and healthcare.

P=N/A, N=200, Recruiting, Dalian Medical University First Affiliated Hospital; Dalian Medical University First Affiliated Hospital

P2/3, N=737, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center